DaanishHodaMD
Oncology • Salt Lake City, UTHematologic Oncology
Oncology Program Associate Medical Director of Hematology Intermountain Health
Dr. Hoda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8 8th Ave
# Lds
Salt Lake City, UT 84143Phone+1 801-408-1819
Summary
- Dr. Hoda is an Oncology Program Associate Medical Director of Hematology and works at the Intermountain Health's Hematologic Malignancy Program performing high risk leukemia treatments and stem cell transplants, and oversees the Classical Hematology Virtual Clinic.
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
University of Miami Leonard M. Miller School of MedicineClass of 2002
Certifications & Licensure
UT State Medical License 2009 - 2026
CO State Medical License 2020 - 2025
ID State Medical License 2020 - 2025
MT State Medical License 2019 - 2025
NV State Medical License 2020 - 2025
FL State Medical License 2006 - 2011
MN State Medical License 2003 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 36 citationsVancomycin-Resistant Enterococcus Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes.Clyde D. Ford, Michaela A. Gazdik, Bert K. Lopansri, Brandon J. Webb, Birgitta Mitchell
Biology of Blood and Marrow Transplantation. 2017-02-01 - 23 citationsRoom contamination, patient colonization pressure, and the risk of vancomycin-resistant Enterococcus colonization on a unit dedicated to the treatment of hematologic m...Clyde D. Ford, Bert K. Lopansri, Michaela A. Gazdik, Brandon J. Webb, Gregory L. Snow
American Journal of Infection Control. 2016-10-01 - 80 citationsLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
The Lancet. Oncology. 2022-08-01
Press Mentions
ASH Recognizes Choosing Wisely, Guideline Implementation ChampionsDecember 29th, 2022- 14 More Utahns Die of COVID-19. And, Yes, We’re Still in a SurgeJuly 7th, 2022
- Approval of Blood Plasma Treatment Has Implications for Utah’s COVID-19 Patients and ResearchersAugust 24th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
